PREZISTA^®/r: Tolerability Proven Over Time

Median Lipid Levels Remained Within NCEP Cutoff Levels From Baseline Through 192 Weeks With
Once-Daily PREZISTA^®/r^{1,
2}

Median Lipid Levels Remained Within NCEP Cutoff Levels From Baseline Through 192 Weeks With Once-Daily PREZISTA®/r

The clinical relevance of this information is unknown.

Use of lipid-lowering agents in ARTEMIS through 192 weeks was 11.7% in the Once-Daily PREZISTA^®/r arm (n=40) and 14.2% in the Kaletra arm (n=49)¹

Selected laboratory abnormalities (≥Grade 2) through 192 weeks³

Selected laboratory abnormalities (≥Grade 2) through 192 weeks

* NCEP (National Cholesterol Education Program) cutoffs: triglycerides <150 mg/dL; LDL <130 mg/dL; total cholesterol <200 mg/dL; HDL >40 mg/dL.²
LDL=low-density lipoprotein; HDL=high-density lipoprotein; TDF/FTC=tenofovir disoproxil fumarate/emtricitabine.
Kaletra (lopinavir/ritonavir) is a registered trademark of AbbVie Inc.

Print Page

Median Lipid Levels Remained Within NCEP Cutoff Levels From Baseline Through 192 Weeks With Once-Daily PREZISTA®/r1, 2

Selected laboratory abnormalities (≥Grade 2) through 192 weeks3

Median Lipid Levels Remained Within NCEP Cutoff Levels From Baseline Through 192 Weeks With
Once-Daily PREZISTA^®/r^{1,
2}

Selected laboratory abnormalities (≥Grade 2) through 192 weeks³